Innocan Pharma (INNPF) Stock Price, Financials & Analysis

Key Stats

Market Cap5.78 Mn

P/E481.28

FCF (Yr)16,000.00

ROA (Yr)-3.45

EV to EBIT1.38

Net Income (Yr)-341,000.00

Enterprise Value1.73 Mn

Add ratio to table…

About

Innocan Pharma Corp is a pharmaceutical tech company that operates under two main segments: Pharmaceuticals and Consumer Wellness. In the Pharmaceutical segment, the company develops innovative drug delivery technologies for both human and animal health applications based on advanced cannabinoids science to treat various conditions and improve quality of life. In the Consumer Wellness segment, the company develops and markets a wide portfolio of innovative and…

Innocan Pharma Corp generates revenue through the sale of its pharmaceutical products and consumer wellness products. In the Pharmaceutical segment, revenue is derived from the development and potential commercialization of its liposomal cannabidiol injection platform (LPT-CBD) for human and animal health applications. In the Consumer Wellness segment, revenue is attributed to sales of B. I. Sky non-CBD personal care products in the United States and Innocan’s CBD personal care products through distribution in Europe.

The company operates through the following segments: Pharmaceuticals and Consumer Wellness.

Pharmaceuticals segment focuses on developing innovative drug delivery technologies for human and animal health applications based on advanced cannabinoids science to treat various conditions and improve quality of life.
Consumer Wellness segment focuses on developing and marketing a wide portfolio of innovative and high-performance self-care and hemp-derived CBD beauty products to promote a healthier lifestyle.

Innocan Pharma Corp positions itself as an innovator in the pharmaceutical and wellness landscapes through proprietary technology, specialized expertise, and a strategic focus on innovation. The company has established a unique position in the management of chronic pain and has made significant inroads in the beauty and wellness sectors. In the pharmaceutical sector, competitors include major pharmaceutical companies, specialty pharma, and generic drug manufacturers, particularly in the cannabinoid space with companies like Jazz Pharmaceuticals. The company’s competitive advantages include its proprietary LPT-CBD injectable platform, robust intellectual property portfolio, experienced mission-driven team, and regulatory alignment with accelerated pathways such as the FDA’s 505(b)(2) application process.

Innocan Pharma Corp serves patients suffering from chronic pain in both human and animal health applications through its Pharmaceuticals segment. In the Consumer Wellness segment, the company serves consumers seeking innovative self-care and beauty products, with a loyal customer base built through online marketplaces and distribution partners.

How Innocan Pharma ranks

Ranked against the 695 companies in Pharmaceuticals and Biotechnology58 metrics · as of Nov 14, 2026

Valuation

12 metrics · Lower multiples rank higher; a negative multiple ranks last

P/E 481xMedian 17.0x 87^th
P/FCF 5.29xMedian 19.0x 98^th
P/Operating cash flow —Median 16.4x No data —
P/S 0.22xMedian 8.38x 96^th
P/B 1.03xMedian 2.04x 70^th
P/Tangible book 1.03xMedian 2.31x 73^rd
EV/EBITDANet cash exceeds market value −0.70xMedian 14.6x Not meaningful —
EV/EBITNet cash exceeds market value −0.73xMedian 18.4x Not meaningful —
EV/RevenueNet cash exceeds market value −0.03xMedian 6.34x Not meaningful —
EV/FCFNet cash exceeds market value −0.83xMedian 23.4x Not meaningful —
EV/Operating cash flow —Median 19.3x No data —
PEG (3Y EPS CAGR) —Median 0.43 No data —

Growth

14 metrics · Year-on-year growth and three-year compound annual growth

Revenue growth (1Y) −9.6%Median 12.7% 30^th
Revenue CAGR (3Y) —Median 11.2% No data —
Gross profit growth (1Y) −8.6%Median 12.8% 28^th
Gross profit CAGR (3Y) —Median 12.2% No data —
Operating income growth (1Y) 0.6%Median −4.0% 53^rd
Operating income CAGR (3Y) —Median 1.1% No data —
Net income growth (1Y) −30.2%Median −6.1% 37^th
Net income CAGR (3Y) —Median 0.3% No data —
EPS growth (1Y) —Median 21.9% No data —
EPS CAGR (3Y) —Median 25.9% No data —
Operating cash flow growth (1Y) —Median −1.8% No data —
Operating cash flow CAGR (3Y) —Median 0.9% No data —
Free cash flow growth (1Y) 203%Median −2.0% 96^th
Free cash flow CAGR (3Y) —Median 2.0% No data —

Profitability

14 metrics · Margins, returns on capital and the quality of earnings

Gross margin 89.9%Median 73.7% 74^th
EBITDA margin 4.9%Median −255% 78^th
Operating margin 4.7%Median −263% 80^th
Pretax margin 0.3%Median −211% 79^th
Net margin 0.0%Median −187% 78^th
FCF margin 4.1%Median −173% 78^th
Operating cash flow margin —Median −183% No data —
Return on equity −7.2%Median −56.4% 81^st
Return on assets −3.2%Median −42.1% 82^nd
Return on invested capital —Median −8.8% No data —
Return on capital employed 13.3%Median −48.0% 92^nd
Asset turnover 2.46xMedian 0.18x 99^th
Cash conversion (OCF / net income) —Median 1.01x No data —
Stock comp / revenue 5.5%Median 31.1% 81^st

Financial Health

11 metrics · Leverage, liquidity and solvency; less debt ranks higher

Debt / assets —Median 16.2% No data —
Debt / equity —Median 0.19x No data —
Net debt / EBITDA —Median 1.21x No data —
Debt / FCF —Median 3.63x No data —
Liabilities / assets 46.8%Median 32.1% 39^th
Equity / assets 53.2%Median 67.9% 39^th
Interest coverage 5.48xMedian −14.3x 87^th
Current ratio 7.70xMedian 4.47x 70^th
Quick ratio 4.94xMedian 3.92x 59^th
Cash ratio 4.94xMedian 3.53x 60^th
Altman Z-score −0.13Median −0.65 53^rd

S.No.	Ticker	Company	Market Cap	P/E	P/S	Total Debt (Qtr)
1	LLY	ELI LILLY & Co	1,359.75 Bn	46.74	15.73	49.50 Bn
2	JNJ	Johnson & Johnson	688.76 Bn	42.83	6.93	44.65 Bn
3	ABBV	AbbVie Inc.	521.69 Bn	50.48	7.90	80.90 Bn
4	MRK	Merck & Co., Inc.	364.31 Bn	148.68	5.41	53.78 Bn
5	NVS	Novartis Ag	306.35 Bn	17.91	5.08	-
6	AZN	Astrazeneca Plc	285.96 Bn	25.92	4.82	-6.68 Bn
7	AMGN	Amgen Inc	251.88 Bn	26.83	6.47	54.01 Bn
8	INNPF	INNOCAN PHARMA Corp	0.01 Bn	481.28	0.22	-

S.No.

Ticker

Company

Market Cap

P/E

P/S

Total Debt (Qtr)

LLY

ELI LILLY & Co

1,359.75 Bn

46.74

15.73

49.50 Bn

JNJ

Johnson & Johnson

688.76 Bn

42.83

6.93

44.65 Bn

ABBV

AbbVie Inc.

521.69 Bn

50.48

7.90

80.90 Bn

MRK

Merck & Co., Inc.

364.31 Bn

148.68

5.41

53.78 Bn

NVS

Novartis Ag

306.35 Bn

17.91

5.08

AZN

Astrazeneca Plc

285.96 Bn

25.92

4.82

-6.68 Bn

AMGN

Amgen Inc

251.88 Bn

26.83

6.47

54.01 Bn

INNPF

INNOCAN PHARMA Corp

0.01 Bn

481.28

0.22

Innocan Pharma INNPF

About

How Innocan Pharma ranks

Valuation

Growth

Profitability

Financial Health

Shareholder Returns

Peer Comparison

Innocan Pharma INNPF

About

How Innocan Pharma ranks

Valuation

Growth

Profitability

Financial Health

Shareholder Returns

Peer Comparison

Create an account

Sign In

Reset Password